Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells

被引:106
|
作者
Zhang, Xiaoling [2 ,3 ]
Gu, Lubing [2 ]
Li, Jiansha [2 ]
Shah, Noopur [2 ]
He, Jing [2 ]
Yang, Lin [2 ]
Hu, Qun [3 ]
Zhou, Muxiang [1 ,2 ]
机构
[1] Emory Univ, Div Pediat Hematol Oncol, Sch Med, Dept Pediat,Aflac Canc Ctr, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Blood Disorders Serv, Atlanta, GA 30322 USA
[3] Tongji Hosp, Dept Pediat, Wuhan, Peoples R China
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; P53; TUMOR-SUPPRESSOR; WILD-TYPE P53; IN-VIVO; P53-DEPENDENT APOPTOSIS; GROWTH-INHIBITION; PROSTATE-CANCER; GENE-EXPRESSION; PROTEIN; ONCOGENE;
D O I
10.1158/0008-5472.CAN-10-1546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Berberine, a natural product derived from a plant used in Chinese herbal medicine, is reported to exhibit anticancer effects; however, its mechanism of action is not clearly defined. Herein, we demonstrate that berberine induces apoptosis in acute lymphoblastic leukemia (ALL) cells by downregulating the MDM2 oncoprotein. The proapoptotic effects of berberine were closely associated with both the MDM2 expression levels and p53 status of a set of ALL cell lines. The most potent apoptosis was induced by berberine in ALL cells with both MDM2 overexpression and a wild-type (wt)-p53, whereas no proapoptotic effect was detected in ALL cells that were negative for MDM2 and wt-p53. In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 activation and a subsequent upregulation of MDM2, berberine strongly induced persistent downregulation of MDM2 followed by a steady-state activation of p53. We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation. Given that MDM2-overexpressing cancer cells are commonly chemoresistant, our findings suggest that this naturally derived agent may have a highly useful role in the treatment of cancer patients with refractory disease. Cancer Res; 70(23); 9895-904. (C)2010 AACR.
引用
收藏
页码:9895 / 9904
页数:10
相关论文
共 50 条
  • [21] MDM2 in breast cancer
    Masakazu Toi
    Shigehira Saji
    Akio Suzuki
    Yutaka Yamamoto
    Takeshi Tominaga
    Breast Cancer, 1997, 4 (4) : 264 - 268
  • [22] A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control
    Li, LM
    Liao, J
    Ruland, J
    Mak, TW
    Cohen, SN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) : 1619 - 1624
  • [23] Increased MMPs activity in MDM2 overexpressing cancer cell lines
    Alaseem, Ali
    Venkatesan, Thiagarajan
    Kanagasabai, Thanigaivelan
    Alhazzani, Khalid
    Alobid, Saad
    Dondapati, Priya
    Rathinavelu, Appu
    CANCER RESEARCH, 2017, 77
  • [24] Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells
    Nakamura, S
    Roth, JA
    Mukhopadhyay, T
    ONCOGENE, 2002, 21 (16) : 2605 - 2610
  • [25] Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells
    Seiichi Nakamura
    Jack A Roth
    Tapas Mukhopadhyay
    Oncogene, 2002, 21 : 2605 - 2610
  • [26] Therapeutic Efficacy of p53 Restoration in Mdm2-Overexpressing Tumors
    Li, Qin
    Zhang, Yun
    El-Naggar, Adel K.
    Xiong, Shunbin
    Yang, Peirong
    Jackson, James G.
    Chau, Gilda
    Lozano, Guillermina
    MOLECULAR CANCER RESEARCH, 2014, 12 (06) : 901 - 911
  • [27] Cytotoxic effect of an MDM2-binding peptide on MDM2-overexpressing acute lymphoblastic leukemia cell lines.
    Zhou, MX
    Gu, LB
    Zhu, YR
    Rong, J
    Findley, HW
    Woods, WG
    BLOOD, 2002, 100 (11) : 194A - 194A
  • [28] Targeted MDM2 degradation as a novel and efficacious cancer therapy
    Yang, Jiuling
    Li, Yangbing
    Aguilar, Angelo
    McEachern, Donna
    Przybranowski, Sally
    Fernandez-Salas, Ester
    Lu, Jianfeng
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Calcium Control of MDM2 in Breast Cancer Cells
    Nguyen, Gia Han N.
    Schmitt, John Michael
    FASEB JOURNAL, 2018, 32 (01):
  • [30] Mdm2 E3 ubiquitin ligase function is dispensable for the degradation of Mdm2 itself
    Kim, Tae-Hyung
    Zhang, Yanping
    CANCER RESEARCH, 2013, 73